84 related articles for article (PubMed ID: 2279460)
1. Ocular toxicity in beagle dogs with lortalamine, a non tricyclic antidepressant compound.
Mally C; Thiebault JJ
Drug Chem Toxicol; 1990; 13(4):309-23. PubMed ID: 2279460
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of lortalamine, a new potent non-tricyclic antidepressant.
Depin JC; Betbeder-Matibet A; Bonhomme Y; Muller AJ; Berthelon JJ
Arzneimittelforschung; 1985; 35(11):1655-62. PubMed ID: 4091869
[TBL] [Abstract][Full Text] [Related]
3. Ocular changes in beagle dogs following oral administration of CGS 24565, a potential hypolipidemic agent.
Schiavo DM; Bentley P
Toxicol Sci; 2000 May; 55(1):189-94. PubMed ID: 10788573
[TBL] [Abstract][Full Text] [Related]
4. Ocular toxicity in beagle dogs with an experimental fluoromethane-sulfonanilide sympathomimetic agent.
Steffen GR; Henderson JD; Nelson RA; Case MT; Saunders DR
Drug Chem Toxicol; 1980; 3(2):165-72. PubMed ID: 7227216
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of the anti-depressant lortalamine.
Elsom LF; Biggs SR; Chasseaud LF; Hawkins DR; Pulsford J; Darragh A
Eur J Drug Metab Pharmacokinet; 1985; 10(3):209-15. PubMed ID: 4085522
[TBL] [Abstract][Full Text] [Related]
6. Tyrosinemia produced by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) in experimental animals and its relationship to corneal injury.
Lock EA; Gaskin P; Ellis M; Provan WM; Smith LL
Toxicol Appl Pharmacol; 2006 Aug; 215(1):9-16. PubMed ID: 16580702
[TBL] [Abstract][Full Text] [Related]
7. Corneal neovascularization and ocular irritancy responses in dogs following topical ocular administration of an EP4-prostaglandin E2 agonist.
Aguirre SA; Huang W; Prasanna G; Jessen B
Toxicol Pathol; 2009 Dec; 37(7):911-20. PubMed ID: 20008547
[TBL] [Abstract][Full Text] [Related]
8. Sodium cyanate-induced ocular lesions in the beagle.
Kern HL; Bellhorn RW; Peterson CM
J Pharmacol Exp Ther; 1977 Jan; 200(1):10-6. PubMed ID: 401882
[TBL] [Abstract][Full Text] [Related]
9. Ocular changes induced in the beagle dog by intravenous infusion of a novel dopaminergic compound, FPL 65447.
Kerry PJ; Wakefield ID; Evans JG
Toxicol Pathol; 1993; 21(3):274-82. PubMed ID: 7902612
[TBL] [Abstract][Full Text] [Related]
10. Sodium hyaluronate decreases ocular surface toxicity induced by benzalkonium chloride-preserved latanoprost: an in vivo study.
Yu F; Liu X; Zhong Y; Guo X; Li M; Mao Z; Xiao H; Yang S
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3385-93. PubMed ID: 23620425
[TBL] [Abstract][Full Text] [Related]
11. Ocular adverse effects of neuropsychiatric agents. Incidence and management.
Oshika T
Drug Saf; 1995 Apr; 12(4):256-63. PubMed ID: 7646824
[TBL] [Abstract][Full Text] [Related]
12. NT-proBNP as a biomarker for the assessment of a potential cardiovascular drug-induced liability in beagle dogs.
Crivellente F; Tontodonati M; Fasdelli N; Casartelli A; Dorigatti R; Faustinelli I; Cristofori P
Cell Biol Toxicol; 2011 Dec; 27(6):425-38. PubMed ID: 21823034
[TBL] [Abstract][Full Text] [Related]
13. Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models.
Prasanna G; Fortner J; Xiang C; Zhang E; Carreiro S; Anderson S; Sartnurak S; Wu G; Gukasyan H; Niesman M; Nair S; Rui E; Lafontaine J; Almaden CD; Wells P; Krauss A
Exp Eye Res; 2009 Nov; 89(5):608-17. PubMed ID: 19445930
[TBL] [Abstract][Full Text] [Related]
14. Effects of oral administration of diphenhydramine on pupil diameter, intraocular pressure, tear production, tear film quality, conjunctival goblet cell density, and corneal sensitivity of clinically normal adult dogs.
Evans PM; Lynch GL; Labelle P
Am J Vet Res; 2012 Dec; 73(12):1983-6. PubMed ID: 23176427
[TBL] [Abstract][Full Text] [Related]
15. Alleviating effects of artificial tear instillation on S-1-induced ocular toxicity in dogs.
Kanie S; Fujieda M; Hitotsumachi T; Suzuki S; Morita F; Hakoi K; Yasui H
J Toxicol Sci; 2017; 42(3):291-300. PubMed ID: 28496035
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the toxicity of novel Zn-DTPA tablet formulation in dogs and rats.
Shankar GN; Potharaju S; Green CE
Drug Dev Res; 2014 Feb; 75(1):37-46. PubMed ID: 24648048
[TBL] [Abstract][Full Text] [Related]
17. Clinical progression of ocular injury following arsenical vesicant lewisite exposure.
Tewari-Singh N; Croutch CR; Tuttle R; Goswami DG; Kant R; Peters E; Culley T; Ammar DA; Enzenauer RW; Petrash JM; Casillas RP; Agarwal R
Cutan Ocul Toxicol; 2016 Dec; 35(4):319-28. PubMed ID: 27002633
[TBL] [Abstract][Full Text] [Related]
18. Acute, subacute and chronic oral toxicity studies of the new serotonin (5-HT)3-receptor antagonist ramosetron in beagle dogs.
Tabata H; Matsuzawa T; Hanada T; Ishikawa A; Yamada M; Ozaki H; Izumisawa N; Barker MH; Cox RA; Buist DP
Arzneimittelforschung; 1995 Jul; 45(7):760-6. PubMed ID: 8573218
[TBL] [Abstract][Full Text] [Related]
19. A sub-Tenon's capsule injection of lidocaine induces extraocular muscle akinesia and mydriasis in dogs.
Ahn JS; Jeong MB; Park YW; Lee YS; Lee ER; Kim SH; Lee I; Seo K
Vet J; 2013 Apr; 196(1):103-8. PubMed ID: 23000006
[TBL] [Abstract][Full Text] [Related]
20. A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499.
Chaves AA; Zingaro GJ; Yordy MA; Bustard KA; O'Sullivan S; Galijatovic-Idrizbegovic A; Schuck H; Christian DB; Hoe CM; Briscoe RJ
J Pharmacol Toxicol Methods; 2007; 56(2):103-14. PubMed ID: 17643323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
